Paul Carter
Direktor/Vorstandsmitglied bei HUTCHMED (CHINA) LIMITED
Vermögen: 742 759 $ am 31.05.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| John F. Donovan | M | - |
Concentric Analgesics, Inc.
 Concentric Analgesics, Inc. Packaged SoftwareTechnology Services Concentric Analgesics, Inc. develops novel, non-opioid therapeutics for the management of acute postsurgical and chronic osteoarthritis pain. The company was founded by John F. Donovan, Frank J. Bellizzi and Craig O. Husfeld in 2014 and is headquartered in San Francisco, CA. | 10 Jahre |
| Per Lundin | M | 41 |
Evox Therapeutics Ltd.
 Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | 8 Jahre |
| Anthony Tennyson | M | - | 4 Jahre | |
| Murray Stewart | M | 63 |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 21 Jahre |
| Jonathan Held | M | 38 | 4 Jahre | |
| Craig O. Husfeld | M | - |
Concentric Analgesics, Inc.
Concentric Analgesics, Inc. Packaged SoftwareTechnology Services Concentric Analgesics, Inc. develops novel, non-opioid therapeutics for the management of acute postsurgical and chronic osteoarthritis pain. The company was founded by John F. Donovan, Frank J. Bellizzi and Craig O. Husfeld in 2014 and is headquartered in San Francisco, CA. | 10 Jahre |
| Chahra Khaoua Epouse Louafi | F | 53 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 4 Jahre |
| Wei Guo Su | M | 66 | 19 Jahre | |
| Johannes G. C. P. Schikan | M | 66 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 Jahre |
| Luca Santarelli | M | 55 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 Jahre |
| Sandipkumar S. Kapadia | M | 54 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 4 Jahre |
| John McHutchison | M | 66 |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | 13 Jahre |
| Thomas Woiwode | M | 52 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 Jahre |
| Frank J. Bellizzi | M | 58 |
Concentric Analgesics, Inc.
Concentric Analgesics, Inc. Packaged SoftwareTechnology Services Concentric Analgesics, Inc. develops novel, non-opioid therapeutics for the management of acute postsurgical and chronic osteoarthritis pain. The company was founded by John F. Donovan, Frank J. Bellizzi and Craig O. Husfeld in 2014 and is headquartered in San Francisco, CA. | 10 Jahre |
| Harpreet Singh-Jasuja | M | 50 | 24 Jahre | |
| Stephen P. Squinto | M | 67 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 4 Jahre |
| Edith Shih | F | 71 | 24 Jahre | |
| John Papastergiou | M | - | 3 Jahre | |
| George Scorsis | M | - | 4 Jahre | |
| Michael Atieh | M | 70 | 4 Jahre | |
| Mark Lee | M | 46 | - | |
| Matthew Wood | M | - |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | 8 Jahre |
| Derek Belz | M | - | 2 Jahre | |
| Steffen Walter | M | 47 | 4 Jahre | |
| Bryan Reasons | M | 56 | 5 Jahre | |
| James Ford | M | - | 29 Jahre | |
| Andrew Dickinson | M | 54 | 8 Jahre | |
| Thomas King | M | 69 |
Concentric Analgesics, Inc.
Concentric Analgesics, Inc. Packaged SoftwareTechnology Services Concentric Analgesics, Inc. develops novel, non-opioid therapeutics for the management of acute postsurgical and chronic osteoarthritis pain. The company was founded by John F. Donovan, Frank J. Bellizzi and Craig O. Husfeld in 2014 and is headquartered in San Francisco, CA. | 7 Jahre |
| Heather Mason | F | 63 | 4 Jahre | |
| Graeme Jack | M | 73 | 7 Jahre | |
| Dan Eldar | M | 70 | 8 Jahre | |
| Stephen Page | M | - | 3 Jahre | |
| Chig Fung Cheng | M | 57 | 16 Jahre | |
| Shu Kam Mok | M | 63 | 7 Jahre | |
| Karen Atkin | M | 58 | 3 Jahre | |
| Miriam Meyer | M | - | 15 Jahre | |
| Maria Poulada | F | - | 11 Jahre | |
| Claudia Blattner | M | - | 9 Jahre | |
| Michael Shi | M | 59 | 2 Jahre | |
| Selina Zhang | F | - | 2 Jahre | |
| Cedrik M. Britten | M | 49 | 4 Jahre | |
| Edward Sturchio | M | - | 4 Jahre | |
| Dennis Purcell | M | 68 | 2 Jahre | |
| Amrit Nagpal | M | - |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | - |
| Roger K. Cady | M | - | 8 Jahre | |
| Carsten Reinhardt | M | 57 | 4 Jahre | |
| Adam Stoten | M | - |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | 8 Jahre |
| Ling Yang | F | 44 | 1 Jahre | |
| Arun Dhandayudham | M | - | 2 Jahre | |
| Sarah Gordon-Wild | F | - |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | - |
| Mathias Hothum | M | 58 | 1 Jahre | |
| Arnd Christ | M | 57 | 4 Jahre | |
| Eliot Forster | M | 58 | 4 Jahre | |
| Christian Meyer | M | 56 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | - |
| Graham Rivers | M | - | 26 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Mark Litton | M | 56 | 14 Jahre | |
| Randall Schatzman | M | 69 | 14 Jahre | |
| Matthew Harbaugh | M | 53 | 6 Jahre | |
| Mark Trudeau | M | 62 | 9 Jahre | |
| Christian Hogg | M | 58 | 16 Jahre | |
| Alan Montgomery | M | 70 | 13 Jahre | |
| Jeremy Charles Green | M | 49 | - | |
| Paul Cleveland | M | 67 | - | |
| Melissa Yeager | F | - | 10 Jahre | |
| Angus Russell | M | 68 | 8 Jahre | |
| Kevin Chow | M | 54 | 7 Jahre | |
| Robert Azelby | M | 56 | 1 Jahre | |
| Benjamin Sessa | M | - | - | |
| Larry K. Benedict | M | 63 | 11 Jahre | |
| Christopher Huang | M | 72 | 11 Jahre | |
| Scott Applebaum | M | 57 | - | |
| Antonin Rollet de Fougerolles | M | 59 |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | - |
| Daniel A. Celentano | M | 72 | 1 Jahre | |
| David Walsey | M | - | - | |
| John Latham | M | 64 | 15 Jahre | |
| Riad El-Dada | M | 59 | 1 Jahre | |
| Gordo Whittaker | M | - | - | |
| Kate Butler | F | - | 5 Jahre | |
| Gordon Earle Moore | M | 95 | 17 Jahre | |
| Gary Bridger | M | 61 | 3 Jahre | |
| Richard Whitley | M | 78 | 13 Jahre | |
| Robert Wilson | M | 81 | 11 Jahre | |
| JoAnn Reed | F | 68 | 9 Jahre | |
| J. Carroll | M | 74 | 9 Jahre | |
| David Norton | M | 72 | 5 Jahre | |
| H. Culp | M | 60 | 9 Jahre | |
| Melvin Booth | M | 79 | 5 Jahre | |
| Kneeland Youngblood | M | 69 | 9 Jahre | |
| Clay Siegall | M | 63 | 14 Jahre | |
| John David Coombe | M | 79 | 5 Jahre | |
| Peter Bisgaard | M | 50 | 3 Jahre | |
| Crispin Davis | M | 75 | 10 Jahre | |
| Stephen M. Dow | M | 68 | 13 Jahre | |
| Wendy Yarno | F | 68 | - | |
| Deepa Pakianathan | M | 59 | 6 Jahre | |
| Michael William Davis Howell | M | 76 | 11 Jahre | |
| Diane Gulyas | F | 67 | 5 Jahre | |
| Chi Keung To | M | 72 | 24 Jahre | |
| David Carlucci | M | 69 | 9 Jahre | |
| Patrick Malloy | M | - | - |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 27 | 27,00% |
| Hong Kong | 15 | 15,00% |
| Irland | 14 | 14,00% |
| Vereinigtes Königreich | 14 | 14,00% |
| Deutschland | 13 | 13,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Paul Carter
- Persönliches Netzwerk
